Indications
Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Composition
- Active substance
- ponesimod
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ponvory
- Active substance
- ponesimod
- ATC code
- L04AE04
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- Marketing authorisation holder
- Laboratoires Juvisé Pharmaceuticals
- Status
- Authorised